fda glp-1 enforcement news today Escalates Against Compounded Marketing FDA Moves to Restrict Mass-Marketed

The journal Food Quality and Preference published the study in March under the title Characteristics and food consumption for current, previous, and potential consumers of GPL-1s . Mention of product names does not imply endorsement by the University of Arkansas System Division of Agriculture

IL received advisory/consulting fees and/or other support from: Novo Nordisk, Eli Lilly, Sanofi, Astra Zeneca, Boehringer-Ingelheim, Cytoki Pharma, Johnson and Johnson, Intercept, TARGETPharma, Merck, Pfizer, Valeritas, Zealand Pharma, Shionogi, Carmot Therapeutics, Structure Therapeutics, Bayer, Translational Medical Academy, Mediflix, Biomea, Metsera, Regeneron, The Comm Group, and WebMD

It is increasingly vital that we engage effectively with our stakeholders, including policymakers, civic and community leaders, and the media

GLP-1 receptor agonists are lab-developed compounds that mimic GLP-1 action at receptors

Additional concerns include potential kidney problems in patients with existing kidney disease and acute kidney injury in severe dehydration cases